Trial Profile
Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; Ofatumumab (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 15 Feb 2018 Status changed from active, no longer recruiting to completed.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 4 Mar 2015.
- 23 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.